Laura I Neumeier1, Robert B Thomson2, Martin Reichel3, Kai-Uwe Eckardt3, Peter S Aronson2,4, Felix Knauf5,3. 1. Department of Nephrology and Hypertension, Friedrich Alexander Universität Erlangen-Nürnberg, Erlangen, Germany. 2. Department of Internal Medicine, Section of Nephrology, Yale University School of Medicine, New Haven, Connecticut. 3. Department of Nephrology and Medical Intensive Care, Charité Universitätsmedizin Berlin, Berlin, Germany. 4. Department of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, Connecticut. 5. Department of Internal Medicine, Section of Nephrology, Yale University School of Medicine, New Haven, Connecticut Felix.Knauf@charite.de.
Abstract
BACKGROUND: A state of oxalate homeostasis is maintained in patients with healthy kidney function. However, as GFR declines, plasma oxalate (Pox) concentrations start to rise. Several groups of researchers have described augmentation of oxalate secretion in the colon in models of CKD, but the oxalate transporters remain unidentified. The oxalate transporter Slc26a6 is a candidate for contributing to the extrarenal clearance of oxalate via the gut in CKD. METHODS: Feeding a diet high in soluble oxalate or weekly injections of aristolochic acid induced CKD in age- and sex-matched wild-type and Slc26a6 -/- mice. qPCR, immunohistochemistry, and western blot analysis assessed intestinal Slc26a6 expression. An oxalate oxidase assay measured fecal and Pox concentrations. RESULTS: Fecal oxalate excretion was enhanced in wild-type mice with CKD. This increase was abrogated in Slc26a6 -/- mice associated with a significant elevation in plasma oxalate concentration. Slc26a6 mRNA and protein expression were greatly increased in the intestine of mice with CKD. Raising Pox without inducing kidney injury did not alter intestinal Slc26a6 expression, suggesting that changes associated with CKD regulate transporter expression rather than elevations in Pox. CONCLUSIONS: Slc26a6-mediated enteric oxalate secretion is critical in decreasing the body burden of oxalate in murine CKD models. Future studies are needed to address whether similar mechanisms contribute to intestinal oxalate elimination in humans to enhance extrarenal oxalate clearance.
BACKGROUND: A state of oxalate homeostasis is maintained in patients with healthy kidney function. However, as GFR declines, plasma oxalate (Pox) concentrations start to rise. Several groups of researchers have described augmentation of oxalate secretion in the colon in models of CKD, but the oxalate transporters remain unidentified. The oxalate transporter Slc26a6 is a candidate for contributing to the extrarenal clearance of oxalate via the gut in CKD. METHODS: Feeding a diet high in soluble oxalate or weekly injections of aristolochic acid induced CKD in age- and sex-matched wild-type and Slc26a6 -/- mice. qPCR, immunohistochemistry, and western blot analysis assessed intestinal Slc26a6 expression. An oxalate oxidase assay measured fecal and Pox concentrations. RESULTS: Fecal oxalate excretion was enhanced in wild-type mice with CKD. This increase was abrogated in Slc26a6 -/- mice associated with a significant elevation in plasma oxalate concentration. Slc26a6 mRNA and protein expression were greatly increased in the intestine of mice with CKD. Raising Pox without inducing kidney injury did not alter intestinal Slc26a6 expression, suggesting that changes associated with CKD regulate transporter expression rather than elevations in Pox. CONCLUSIONS:Slc26a6-mediated enteric oxalate secretion is critical in decreasing the body burden of oxalate in murine CKD models. Future studies are needed to address whether similar mechanisms contribute to intestinal oxalate elimination in humans to enhance extrarenal oxalate clearance.
Authors: John F Heneghan; Arash Akhavein; Maria J Salas; Boris E Shmukler; Lawrence P Karniski; David H Vandorpe; Seth L Alper Journal: Am J Physiol Cell Physiol Date: 2010-03-10 Impact factor: 4.249
Authors: Robert W Freel; Jonathan M Whittamore; Marguerite Hatch Journal: Am J Physiol Gastrointest Liver Physiol Date: 2013-07-25 Impact factor: 4.052
Authors: Zhirong Jiang; John R Asplin; Andrew P Evan; Vazhaikkurichi M Rajendran; Heino Velazquez; Timothy P Nottoli; Henry J Binder; Peter S Aronson Journal: Nat Genet Date: 2006-03-12 Impact factor: 38.330
Authors: Jeffrey S Clark; David H Vandorpe; Marina N Chernova; John F Heneghan; Andrew K Stewart; Seth L Alper Journal: J Physiol Date: 2008-01-03 Impact factor: 5.182
Authors: Felix Knauf; Robert B Thomson; John F Heneghan; Zhirong Jiang; Adedotun Adebamiro; Claire L Thomson; Christina Barone; John R Asplin; Marie E Egan; Seth L Alper; Peter S Aronson Journal: J Am Soc Nephrol Date: 2016-06-16 Impact factor: 10.121